Sunday, 18 February 2018

The U.S. Food and Drug Administration granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients

The U.S. Food and Drug Administration said late on Friday it granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients with inoperable mid-stage disease that has not spread widely around the body.
The green light - which had been expected following positive clinical data last year - gives AstraZeneca a chance to intervene earlier in lung cancer, distinguishing it from rivals that have approval for tackling advanced or metastatic disease.
Analysts believe using Imfinzi in so-called stage III lung cancer, where cancer has only spread locally, opens up an annual sales opportunity worth around $2 billion. Importantly, AstraZeneca has a lead of two to three years over other drug companies in this particular area.

No comments:

Post a Comment

Fat, not carbs, is directly linked to weight gain

The research looked at mice on 30 different types of diets. The result of the research found that the mice on a high-fat, low-carb diet ga...